Medtronic MiniMed Insulin Pump Recall Over Battery Failure Risks
MiniMed insulin pumps have a history of problems that have led to numerous recalls over the last decade, following reports of over or under delivery of insulin.
Tag Archives: Insulin
-
-
Tandem T:Connect Recall Issued Over Software Problems Linked to More Than 200 Injuries
Federal health officials encourage anyone using the Tandem t:connect system to carefully monitor the battery levels to prevent unexpected pump failures, which could stop insulin delivery.
-
Medfusion Syringe Pump Recall Issued Over Software Errors
Similar problems have plagued various Medtronic syringe pumps over the last couple years, leading to multiple recalls
-
Fake Ozempic Linked to Hypoglycemia Injuries, Poison Centers Warn
The FDA has reportedly seized thousands of fake Ozempic products over the last year, the report indicates.
-
Omnipod 5 Android App Recalled Due to Insulin Overdose Risk
Nearly 30,000 Omnipod 5 insulin delivery systems are being recalled over the risk that the devices may delivery incorrect insulin doses.
-
Medtronic MiniMed Lawsuit Filed Over Wrongful Death from Insulin Pump Overdose
Wrongful death lawsuit alleges that family was informed of a Medtronic MiniMed recall just days after a fatal insulin pump overdose occurred, when one of the pumps malfunctioned.
-
Insulin Lawsuits Over Price Fixing Centralized in Federal MDL
The U.S. JPML determined that allegations raised in a number of insulin price fixing lawsuits each arise from a common factual core, which makes consolidation of the cases before one federal judge appropriate.
-
JPML to Hear Oral Arguments Over Consolidation of Insulin Pricing Lawsuits Next Month
Five separate states have filed insulin pricing scheme lawsuits against drug manufacturers, and are calling for the cases to be consolidated in a Mississippi federal court.
-
JPML Asked to Centralize Lawsuits Over Insulin Pricing Scheme
Lawsuits allege the insulin pricing scheme leads to states and consumers paying $300 to $700 for doses, which cost the drug makers just $2 to produce.
-
Insulin Overpricing Lawsuit Alleges Drug Makers and PBMs Engaged in Deceptive and Unfair Conspiracy
Rebates disguised as "administrative fees" and other costs lead to an illegal insulin pricing scheme which costs consumers and the healthcare system billions of dollars, the lawsuit claims
